158 related articles for article (PubMed ID: 8174049)
1. Evaluation of a 24-hour infusion of etidronate disodium for the treatment of hypercalcemia of malignancy.
Flores JF; Rude RK; Chapman RA; Belani CP; Chang AY; Pritchard JD; Hoff JV
Cancer; 1994 May; 73(10):2527-34. PubMed ID: 8174049
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of a 24-hour infusion of etidronate disodium in the treatment of hypercalcemia of malignant disease. A dose-ranging pilot study.
Flores JF; Singer FR; Rude RK
Miner Electrolyte Metab; 1991; 17(6):390-5. PubMed ID: 1823390
[TBL] [Abstract][Full Text] [Related]
3. Intravenous etidronate in the management of malignant hypercalcemia.
Ryzen E; Martodam RR; Troxell M; Benson A; Paterson A; Shepard K; Hicks R
Arch Intern Med; 1985 Mar; 145(3):449-52. PubMed ID: 3919667
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia.
Gucalp R; Ritch P; Wiernik PH; Sarma PR; Keller A; Richman SP; Tauer K; Neidhart J; Mallette LE; Siegel R
J Clin Oncol; 1992 Jan; 10(1):134-42. PubMed ID: 1727915
[TBL] [Abstract][Full Text] [Related]
5. Treatment of hypercalcemia of malignancy with intravenous etidronate. A controlled, multicenter study. The Hypercalcemia Study Group.
Singer FR; Ritch PS; Lad TE; Ringenberg QS; Schiller JH; Recker RR; Ryzen E
Arch Intern Med; 1991 Mar; 151(3):471-6. PubMed ID: 1900410
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of oral administration of etidronate disodium in maintaining normal serum calcium levels in previously hypercalcemic cancer patients.
Ringenberg QS; Ritch PS
Clin Ther; 1987; 9(3):318-25. PubMed ID: 3111705
[TBL] [Abstract][Full Text] [Related]
7. A randomized double-blind study of gallium nitrate compared with etidronate for acute control of cancer-related hypercalcemia.
Warrell RP; Murphy WK; Schulman P; O'Dwyer PJ; Heller G
J Clin Oncol; 1991 Aug; 9(8):1467-75. PubMed ID: 1906532
[TBL] [Abstract][Full Text] [Related]
8. Etidronate disodium for treating hypercalcaemia of malignancy: a double blind, placebo-controlled study.
Hasling C; Charles P; Mosekilde L
Eur J Clin Invest; 1986 Oct; 16(5):433-7. PubMed ID: 3100312
[TBL] [Abstract][Full Text] [Related]
9. Intravenous disodium etidronate therapy in Paget's disease of bone and hypercalcemia of malignancy. Effects on biochemical parameters and bone histomorphometry.
Meunier PJ; Chapuy MC; Delmas P; Charhon S; Edouard C; Arlot M
Am J Med; 1987 Feb; 82(2A):71-8. PubMed ID: 3103438
[TBL] [Abstract][Full Text] [Related]
10. Etidronate disodium in the management of malignancy-related hypercalcemia.
Hasling C; Charles P; Mosekilde L
Am J Med; 1987 Feb; 82(2A):51-4. PubMed ID: 3103436
[TBL] [Abstract][Full Text] [Related]
11. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.
Nussbaum SR; Younger J; Vandepol CJ; Gagel RF; Zubler MA; Chapman R; Henderson IC; Mallette LE
Am J Med; 1993 Sep; 95(3):297-304. PubMed ID: 8368227
[TBL] [Abstract][Full Text] [Related]
12. Neoplastic hypercalcemia: physiologic response to intravenous etidronate disodium.
Jacobs TP; Gordon AC; Silverberg SJ; Shane E; Reich L; Clemens TL; Gundberg CM
Am J Med; 1987 Feb; 82(2A):42-50. PubMed ID: 3030098
[TBL] [Abstract][Full Text] [Related]
13. Effects of intravenous etidronate disodium on skeletal and calcium metabolism.
Kanis JA; Urwin GH; Gray RE; Beneton MN; McCloskey EV; Hamdy NA; Murray SA
Am J Med; 1987 Feb; 82(2A):55-70. PubMed ID: 3103437
[TBL] [Abstract][Full Text] [Related]
14. Effect of salmon calcitonin and etidronate on hypercalcemia of malignancy.
Fatemi S; Singer FR; Rude RK
Calcif Tissue Int; 1992 Feb; 50(2):107-9. PubMed ID: 1571826
[TBL] [Abstract][Full Text] [Related]
15. Role of the bisphosphonate etidronate in the therapy of cancer-related hypercalcemia.
Singer FR
Semin Oncol; 1990 Apr; 17(2 Suppl 5):34-9. PubMed ID: 2110387
[TBL] [Abstract][Full Text] [Related]
16. A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy.
Kawada K; Minami H; Okabe K; Watanabe T; Inoue K; Sawamura M; Yagi Y; Sasaki T; Takashima S
Jpn J Clin Oncol; 2005 Jan; 35(1):28-33. PubMed ID: 15681601
[TBL] [Abstract][Full Text] [Related]
17. Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone.
Gucalp R; Theriault R; Gill I; Madajewicz S; Chapman R; Navari R; Ahmann F; Zelenakas K; Heffernan M; Knight RD
Arch Intern Med; 1994 Sep; 154(17):1935-44. PubMed ID: 8074597
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of immobilization hypercalcemia using calcitonin and etidronate.
Meythaler JM; Tuel SM; Cross LL
Arch Phys Med Rehabil; 1993 Mar; 74(3):316-9. PubMed ID: 8439262
[TBL] [Abstract][Full Text] [Related]
19. Parenteral diphosphonates for treating malignant hypercalcemia.
Jung A; van Ouwenaller C; Chantraine A; Courvoisier B
Cancer; 1981 Oct; 48(8):1922-5. PubMed ID: 6456809
[TBL] [Abstract][Full Text] [Related]
20. Denosumab for treatment of hypercalcemia of malignancy.
Hu MI; Glezerman IG; Leboulleux S; Insogna K; Gucalp R; Misiorowski W; Yu B; Zorsky P; Tosi D; Bessudo A; Jaccard A; Tonini G; Ying W; Braun A; Jain RK
J Clin Endocrinol Metab; 2014 Sep; 99(9):3144-52. PubMed ID: 24915117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
